{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"XBiotech Inc."},"Symbol":{"label":"Symbol","value":"XBIT"},"Address":{"label":"Address","value":"5217 WINNEBAGO LANE, AUSTIN, Texas, 78744, United States"},"Phone":{"label":"Phone","value":"+1 512 386-2900"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States."},"CompanyUrl":{"label":"Company Url","value":"http://www.xbiotech.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Ashley Otero","title":"Vice President-Clinical Operations"},{"name":"John Simard","title":"Chairman, President & Chief Executive Officer"},{"name":"Mark Ziats","title":"Medical Director"},{"name":"Sushma Shivaswamy","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}